BSE · 534920
iSERA Lifesciences Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Shareholding
As of 2026-06-30
- Promoter58.63%
- Public41.37%
1,014 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 28.44× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — GSM · GSM 0 · ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
- Reported zero revenue in 6 of the last 8 disclosed periods.
- 52-week range spans 28.44× (₹5.06 to ₹143.9) — an unusually wide band.
Peer comparison
Computers - Software - Medium / Small · ranked #143 of 284 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| PB FinTech Limited | ₹83,285 Cr | 111.32 | 11.41 | 9.16% | 10.2% |
| Tata Technologies Limited | ₹31,633 Cr | 48.6 | 9.78 | 15.63% | 9.4% |
| Inventurus Knowledge Solutions Ltd. | ₹30,620 Cr | 40.09 | 10.92 | 25.77% | 22.82% |
| Affle 3i Limited | ₹22,462 Cr | 47.01 | 6.11 | 12.45% | 16.85% |
| Tata Elxsi Limited | ₹21,240 Cr | 30.13 | 6.98 | 22.89% | 16.84% |
| Sagility Limited | ₹20,790 Cr | 20.19 | 2.16 | 9.57% | 13.04% |
| Pine Labs Limited | ₹19,981 Cr | 154.62 | 3.39 | 1.91% | 4.5% |
| eClerx Services Ltd. | ₹17,868 Cr | 24.51 | 6.13 | 27.57% | 16.81% |
| Firstsource Solutions Ltd. | ₹17,771 Cr | 22.26 | 4.05 | 17.13% | 6.61% |
| KPIT Technologies Ltd. | ₹15,105 Cr | 24.19 | 4.26 | 18% | 8.84% |
| iSERA Lifesciences Ltd.(this company) | ₹121 Cr | 464.19 | 14.67 | 3.15% | -4.44% |
AI analysis
AI-generated · google/gemini-2.5-flashiSERA Lifesciences Ltd. is listed with a market capitalization of Rs 121 Cr. The company reported revenue of Rs 25.69 Cr and a profit margin of 19.26%. Earnings per share (EPS) stood at Rs 0.31. The promoter holding is 58.63%, with no promoter shares pledged. The stock's 52-week high was Rs 143.9 and the 52-week low was Rs 2.74.
Positives
- +Promoter holding is 58.63%, indicating significant insider ownership.
- +No promoter shares are pledged, with a pledge percentage of 0%.
- +Return on equity (ROE) is 314.5%, indicating high profitability relative to shareholders' equity.
Negatives
- −The trailing twelve-month PE ratio is high at 464.19.
- −Debt to equity ratio is significantly high at 19.95.
- −Return on capital employed (ROCE) is relatively low at 3.39%.
- −The stock is currently under regulatory surveillance, including GSM and ESM measures.
- −Quarterly revenue has been inconsistent, with revenue of Rs 0 Cr for several quarters in 2025.
Financial performance
The company reported revenue of Rs 25.69 Cr. The latest annual earnings per share (EPS) is Rs 0.31. For the quarter ending March 2026, revenue was Rs 1.16 Cr and net profit was Rs 0.55 Cr. In the preceding quarter ending December 2025, revenue was Rs 0.19 Cr with a net loss of Rs 0.28 Cr.
Profitability & returns
iSERA Lifesciences Ltd. achieved a profit margin of 19.26%. The return on capital employed (ROCE) was 3.39%. The company's return on equity (ROE) was 314.5%.
Balance sheet
The company's debt-to-equity ratio is 19.95. The book value per share is Rs 9.81.
Ownership & pledges
The public shareholding is 41.37%. There are no FII or DII holdings reported. The number of shareholders is 1014 for the same period. The promoter holding has not been provided for previous periods.
Regulatory & surveillance
The company's stock is currently under regulatory surveillance measures, specifically GSM and ESM. The applied measures are listed as "GSM · GSM 0 · ESM · ESM 2".
Data as of — price: 2026-09-11 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.